Abeona Therapeutics (ABEO) Assets Average (2011 - 2026)

Abeona Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $209.0 million for Q1 2026.

• On a quarterly basis, Assets Average rose 100.71% year-over-year to $209.0 million in Q1 2026; TTM through Mar 2026 was $209.0 million, a 100.71% increase from a year earlier, with the FY2025 full-year figure at $164.3 million, up 89.96% from the prior year.
• Assets Average eased to $209.0 million in Q1 2026 per ABEO's latest filing, from $225.3 million in the prior quarter.
• Across five years, Assets Average topped out at $238.7 million in Q3 2025 and bottomed at $41.7 million in Q3 2022.
• The 5-year median for Assets Average is $69.4 million (2024), against an average of $106.7 million.
• Across the five-year window, Assets Average tumbled 66.57% in 2022 and surged 112.81% in 2024, its largest moves.
• Year by year, Assets Average stood at $51.5 million in 2022, then rose by 26.33% to $65.0 million in 2023, then soared by 76.44% to $114.8 million in 2024, then soared by 96.35% to $225.3 million in 2025, then declined by 7.23% to $209.0 million in 2026.
• Per Business Quant, the three latest ABEO Assets Average figures stand at $209.0 million (Q1 2026), $225.3 million (Q4 2025), and $238.7 million (Q3 2025).